Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
May 16, 2023
Robot's Smart Move: SNDL Trade Generates 5.46% Gain

Robot's Smart Move: SNDL Trade Generates 5.46% Gain

In the realm of AI-driven trading robots, Swing Trader: Deep Trend Analysis (TA) has emerged as a top performer within Tickeron's robot factory. With an impressive weekly return of 5.46% for SNDL (Sundial Growers Inc.), this AI trading robot has caught the attention of investors. Additionally, the recent bullish crossover between the 10-day and 50-day moving averages further strengthens the case for a potential buy signal. In this article, we will delve into the technical analysis and explore the implications of SNDL's recent earnings report.

Analyzing the Bullish Trend: On May 9, 2023, SNDL's 10-day moving average crossed bullishly above its 50-day moving average. This development indicates a shift towards a higher trend, potentially signaling a favorable buying opportunity. Historical data reveals that in 7 out of 8 previous instances where the 10-day moving average crossed above the 50-day moving average, the stock continued to rise over the following month. This suggests an 88% probability of a sustained upward trend in the near future.

Earnings Report and Market Capitalization: The most recent earnings report for SNDL was released on May 15, providing valuable insights into the company's financial performance. The report revealed earnings per share (EPS) of -14 cents, which missed the estimated figure of 0 cents. This underperformance may have contributed to fluctuations in the stock price and could impact investor sentiment. SNDL currently has 353.32K shares outstanding, resulting in a market capitalization of 439.57M.

Implications for Investors: While the bullish trend formation and the Swing Trader AI Robot's successful track record offer an optimistic outlook for SNDL, it is important for investors to consider both technical and fundamental factors before making any investment decisions.

The bullish crossover between the 10-day and 50-day moving averages indicates a potential buying opportunity, but it should be complemented with comprehensive research and analysis of the company's fundamentals. Evaluating SNDL's business model, competitive position, revenue growth, and management strategies can provide a more holistic view of the investment opportunity.

The recent earnings report, with the company falling short of estimated EPS, may raise concerns among investors. It highlights the importance of closely monitoring future earnings reports and analyzing the reasons behind the deviation from expectations. Understanding SNDL's financial health, debt levels, and potential growth drivers will enable investors to make informed decisions based on a comprehensive assessment of the company's fundamentals.

Conclusion: SNDL's performance in Tickeron's robot factory, combined with the bullish trend formation resulting from the crossover of moving averages, offers an encouraging outlook for potential investors. However, it is crucial to conduct thorough research and analysis, considering both technical indicators and fundamental aspects, before making any investment decisions. The recent earnings report serves as a reminder of the need to closely monitor SNDL's financial performance going forward.

Related Ticker: SNDL

Contributor

Dem Sem's AvatarDem Sem|Expert

SNDL in upward trend: price may jump up because it broke its lower Bollinger Band on July 28, 2026

SNDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where SNDL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SNDL's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for SNDL just turned positive on August 07, 2026. Looking at past instances where SNDL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDL as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNDL entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (4.922). P/E Ratio (0.000) is within average values for comparable stocks, (133.675). SNDL's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.038). SNDL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.050). P/S Ratio (0.480) is also within normal values, averaging (8.440).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SNDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.

Industry description

The alcoholic beverage market includes beer, wine, and spirits. From $230 billion in 2015, the industry has grown to around $250 billion by 2019. In recent years, alcoholic beverage makers have been looking to expand distribution and purchase channels, such as through online stores (e.g. e-commerce platform Drizly) and convenience stores. Anheuser-Busch In Bev and Diageo are major global alcoholic beverage companies, while U.S.-owned companies include Constellation Brands and Brown-Forman Corp. among several others.

Market Cap

The average market capitalization across the Beverages: Alcoholic Industry is 5.46B. The market cap for tickers in the group ranges from 1.5K to 19.33T. PBGDF holds the highest valuation in this group at 19.33T. The lowest valued company is SRSG at 1.5K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Alcoholic Industry was 0%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was -31%. SBEV experienced the highest price growth at 17%, while YHC experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Beverages: Alcoholic Industry was -87%. For the same stocks of the Industry, the average monthly volume growth was 8% and the average quarterly volume growth was 62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 70
SMR Rating: 97
Profit Risk Rating: 100
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
SNDL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a producer, distributer, and seller of cannabis

Industry BeveragesAlcoholic

Profile
Details
Industry
N/A
Address
919-11 Avenue South West
Phone
+1 403 948-5227
Employees
2604
Web
https://www.sndl.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.